Type of mesh and wall plane in prophylactic mesh after stoma closure: A network meta-analysis
- Open Access
- 01.12.2025
- Review
Abstract
Introduction
Methods
Information sources and search strategy
Study selection
Eligibility criteria
Data Extraction
Outcome measures
Risk of bias and quality control
Statistical analysis
Results
Study selection and characteristics of included studies
Study | Study design/country | Participants | Type of mesh | Wall plane | Incisional hernia | Surgical site infection | Follow-up |
|---|---|---|---|---|---|---|---|
Liu, 2013 [15] | Retrospective cohort/Australia | Ileostomy closure. Mesh (n = 47). No mesh (n = 36) | Polypropylene mesh (Ultrapro, Ethicon, Johnson & Johnson) | Onlay | Mesh group: 3 (6.4%) No mesh group: 13 (36.1%) | Mesh group: 2 (4.3%) No mesh group: 1 (2.8%) | Mesh group: Median 18.0 months (IQR: 13.8–26.2) No mesh group: Median 21.1 months (IQR: 10.1–33.9) |
Maggiori, 2015 [16] | Ambispective cohort/France | Ileostomy closure. Mesh (n = 30). No mesh (n = 64) | Bioprosthetic, non–cross-linked collagen, porcine dermal matrix with 1.4 mm thickness (Meccellis BioTech, France) | Retromuscular | Mesh group: 1 (3%) No mesh group: 15 (24%) | Mesh group: 2 (7%) No mesh group: 3 (5%) | Mesh group: 16.8 ± 3.3 months No mesh group: 39.2 ± 16.9 months |
Warren, 2018 [17] | Retrospective cohort/United States | Colostomy closure (n = 212). Ileostomy closure (n = 147). Mesh (n = 91). No mesh (n = 268) | Ultrapro® (n = 19; Ethicon Inc), Prolene® Soft (n = 24; Ethicon), Vitamesh™ (n = 42), Bard Soft (n = 3; Bard/Davol) and Vitamesh Blue™ (n = 3) | Retromuscular | Mesh group: 1 (1.1%) No mesh group: 49 (17.2%) | Mesh group: 18 (20%) No mesh group: 53 (19.8%) | Mesh group: 10 +/− 9.6 No mesh group: 19.5 +/− 19.4 |
Bhangu, 2020 [18] | Randomized controlled trial/United Kingdom | Colostomy closure (n = 159). Ileostomy closure (n = 631). Mesh (n = 394). No mesh (n = 396) | Biological mesh (non-crosslinked porcine collagen tissue matrix) | Intraperitoneal | Mesh group: 39 (12%) No mesh group: 64 (20%) | Mesh group: 60 (16%) No mesh group: 49 (13%) | Mesh group: At 2-year follow-up, 95% of expected patients completed follow-up No mesh group: At 2-year follow-up, 94% of expected patients completed follow-up |
Lee, 2020 | Retrospective cohort/Korea | Ileostomy closure. Mesh (n = 15). No mesh (n = 18) | Biological mesh (non-crosslinked porcine dermal biologic mesh (XCM Biologic Tissue Matrix, Johnson & Johnson Medical) | Onlay | Mesh group: 2 (13.3%) No mesh group: 1 (5.6%) | Mesh group: 0 (0%) No mesh group: 2 (11.1%) | Mesh group: Median 22.0 months (IQR: 20.0–30.0) No mesh group: Median 26.5 months (IQR: 15.5–33.0) |
Pizza, 2020 [19] | Ambispective cohort/Italy | Ileostomy closure. Mesh (n = 26). No mesh (n = 58) | Biosynthetic (GORE BIO-A) | Onlay | Mesh group: 1 (3.8%) No mesh group: 19 (32.7.%) | Mesh group: 1 (3.8%) No mesh group: 2 (3.4%) | Mesh group: 15.4 ± 2.3 months No mesh group: 37.2 ± 26.9 months |
Wong, 2020 [20] | Retrospective cohort/Australia | Ileostomy closure. Mesh (n = 81). No mesh (n = 192) | Polypropylene (Surgipro; Covidien) | Onlay | Mesh group: 1 (1.2%) No mesh group: 18 (9.4%) | Mesh group: 3 (3.7%) No mesh group: 6 (3.1%) | Mesh group: 33 months (Range: 0–107) No mesh group: 33 months (Range: 0–122) |
Siddiqui, 2023 [21] | Retrospective cohort/United States | Colostomy closure (n = 19). Ileostomy closure (n = 48). Mesh (n = 67) | Bioprosthetic, poly-4-hydroxybutyrate mesh (BARD PhasixTM mesh) (n = 3), and a biological mesh (n = 37) (Allergan STRATTICE™: Madison NJ n = 34, BARD XenMatrixTM AB Surgical Graft n = 1 and BIOHORIZON Allergan AlloDerm Regenerative Tissue Matrix n = 2) | Onlay (n = 27) Retromuscular (n = 40) | Onlay: 4 (14.8%) Retrosmuscular: 2 (5%) Bioprosthetic mesh: 2 (6.7%) Biological mesh: 4 (10.8%) | Not reported | Not reported |
Katyar, 2023 [22] | Randomized controlled trial/Pakistan | Ileostomy closure (n = 94) | Prosthetic mesh (n = 46) Biological mesh (n = 48) | Retromuscular | Not reported | Synthetic mesh: 1 (2%) Biological mesh: 2 (4%) | 30 days |
Vu, 2024 [23] | Retrospective cohort/United States | Colostomy closure (n = 46). Ileostomy closure (n = 128). Mesh (n = 101). No mesh (n = 73) | Biosynthetic (GORE BIO-A) | Retromuscular | Mesh group: 1 (1%) No mesh group: 13 (17.8%) | Mesh group: 1 (1%) No mesh group: 7 (9.6%) | Mesh group: Median 45.2 months (Range: 0.79–74.3) No mesh group: Median 43.2 (Range: 0.82–69.0) |
Randomized controlled trial/Finland | Ileostomy closure (n = 94) | Prosthetic mesh (n = 47) Biological mesh (n = 50) | Retromuscular | Synthetic mesh: 2 (4%) Biological Mesh: 2 (4%) | Synthetic mesh: 1 (2%) Biological mesh: 2(4%) | 10 months |
Type of mesh and incisional hernia
Type of mesh and incisional hernia | ||
|---|---|---|
P-score | SUCRA | |
Prosthetic | 0.8740 | 0.8521 |
Bioprosthetic | 0.7855 | 0.7753 |
Biological | 0.3394 | 0.3480 |
No mesh | 0.0010 | 0.0244 |
Type of mesh and surgical site infection | ||
Bioprosthetic | 0.7600 | 0.7084 |
No mesh | 0.5149 | 0.4899 |
Prosthetic | 0.4917 | 0.4951 |
Biological | 0.2334 | 0.3064 |
Wall plane for the mesh and incisional hernia | ||
Retromuscular | 0.9928 | 0.9702 |
Onlay | 0.6641 | 0.6211 |
Intraperitoneal | 0.3414 | 0.3430 |
No mesh | 0.0017 | 0.0656 |
Wall plane for the mesh and surgical site infection | ||
Retromuscular | 0.6543 | 0.6327 |
Onlay | 0.5119 | 0.5193 |
No mesh | 0.4891 | 0.4992 |
Intraperitoneal | 0.3448 | 0.3486 |